Genprex, Inc. (GNPX)
$3.65+$0.04 (+1.11%) Today
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
No Form 4 activity for GNPX in the last 90 days.
10 Form 4 filings on record, the earliest from Dec 6, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Brent M. Longnecker - Director | Open-market sale | Common Stock | 8 | $27.06 | $10 | |
| Brent M. Longnecker - Director | Open-market sale | Common Stock | 10 | $27.06 | $12 | |
| Mark Stanley Berger - Officer | Tax withholding / forfeiture | Common Stock | 7,168 | $44.00 | $14K | |
| Ryan M. Confer - Officer | Tax withholding / forfeiture | Common Stock | 9,330 | $44.00 | $19K | |
| Mark Stanley Berger - Officer | Tax withholding / forfeiture | Common Stock | 4,500 | $250.69 | $1K | |
| Ryan M. Confer - Officer | Tax withholding / forfeiture | Common Stock | 5,775 | $250.69 | $1K | |
| Mark Stanley Berger - Officer | Grant or award | Common Stock | 18,250 | $0.00 | - | |
| Toscano Jose Antonio Moreno - Director | Grant or award | Common Stock | 4,750 | $0.00 | - | |
| Ryan M. Confer - Officer | Grant or award | Common Stock | 29,375 | $0.00 | - | |
| William R. Wilson Jr. - Director | Grant or award | Common Stock | 4,750 | $0.00 | - | |
| Brent M. Longnecker - Director | Grant or award | Common Stock | 4,750 | $0.00 | - |
Genprex, Inc. (GNPX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-15. The full record for GNPX runs to 10 Form 4 filings, the earliest from 2024-12-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GNPX were filed in the last 90 days.
No insider sales of GNPX were filed in the last 90 days. 2 sales are on record for this company.
This page tracks GNPX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GNPX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
